To assess whether statin use improves local control (LC) in patients undergoing organ-preserving trimodality therapy for muscle-invasive bladder cancer.
We retrospectively analyzed the data from 286 patients with muscle-invasive, transitional cell carcinoma of the bladder treated with maximal transurethral resection of the bladder tumor followed by chemoradiotherapy from 1986 to 2003 at the Massachusetts General Hospital. Patients with a complete response after induction chemoradiotherapy received consolidation chemoradiotherapy and those with an incomplete response underwent cystectomy. Of the 286 patients, 35 (12%) were known to be taking a statin during chemoradiotherapy. LC was defined as freedom from the development of muscle-invasive bladder cancer or superficial bladder cancer necessitating cystectomy.
The median follow-up time was 2.7 years for all patients and 3.1 years for survivors. The overall 5-year LC rate was 55%. On univariate analysis, tumor stage, completeness of transurethral resection of the bladder tumor, hydronephrosis, chemotherapy type, treatment era, and statin use were significantly associated with LC. The 5-year LC rate for patients taking a statin was 73% versus 52% for patients not taking a statin (P = 0.04). On multivariate analysis incorporating covariates that were statistically significant (P <0.05) on univariate analysis, only chemotherapy with cisplatin (P = 0.02) and the absence of hydronephrosis (P = 0.01) remained significantly associated with LC.
Statin use was associated with an improvement in LC on univariate analysis but was not found to be independently associated with LC after controlling for known prognostic factors. The potential beneficial interaction between statin use and chemoradiotherapy in bladder cancer warrants further investigation in a prospective study.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Urology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery.JAMA. 1987; 258: 931-935
- Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.Urology. 2002; 60: 62-67
- Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.J Clin Oncol. 2002; 20: 3061-3071
- Overview of bladder cancer trials in the Radiation Therapy Oncology Group.Cancer. 2003; 97: 2115-2119
- Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate: implications for increased therapeutic ratio of low dose rate irradiation.Am J Clin Oncol. 1985; 8: 517-522
- The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation.Science. 1988; 239: 645-647
- Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines.Cancer Res. 2000; 60: 6597-6600
- The RAS signal transduction pathway and its role in radiation sensitivity.Oncogene. 2003; 22: 5866-5875
- Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation.Int J Cancer. 1993; 53: 302-307
- Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.Cancer Treat Rev. 2004; 30: 609-641
- Therapy insight: potential of statins for cancer chemoprevention and therapy.Nat Clin Pract Oncol. 2005; 2: 82-89
- The potential of statins as part of anti-cancer treatment.Eur J Cancer. 2005; 41: 516-522
- The role of statins in cancer prevention and treatment.Oncology. 2005; 19: 739-750
- Cell cycle-specific effects of lovastatin.Proc Natl Acad Sci USA. 1991; 88: 3628-3632
- Atorvastatin: a potential chemopreventive agent in bladder cancer.Urology. 2005; 66: 1209-1212
- Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.Clin Cancer Res. 1996; 2: 483-491
- Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma.Invest New Drugs. 2001; 19: 81-83
- Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma: a randomized controlled trial.Br J Cancer. 2001; 84: 886-891
- Statin use is associated with improved biochemical outcome after high-dose radiotherapy for clinically localized prostate cancer.Int J Radiat Oncol Biol Phys. 2003; 57 (abstract): S271
- Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.Int J Radiat Oncol Biol Phys. 2005; 62: 1363-1370
- Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.Urology. 2005; 66: 1150-1154
- A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.Urol Oncol. 2005; 23: 143-149
- Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase.J Biol Chem. 1998; 273: 24266-24271
- Rho GTPases: potential candidates for anticancer therapy.Cancer Lett. 2004; 206: 181-191
- Trends in Statin Use in the Civilian Noninstitutionalized Medicare Population, 1997 and 2002. Agency for Healthcare Research and Quality, Rockville, MD2005 (http://www.meps.ahrq.gov/papers/st97/stat97.pdf. Accessed January 27, 2006.)
Published online: December 04, 2006
Accepted: August 17, 2006
Received: April 19, 2006
© 2006 Elsevier Inc. Published by Elsevier Inc. All rights reserved.